Relypsa, Inc.

Ilypsa, Inc.

Abbott Laboratories Corporation

Tricida, Inc.

Renosis, Inc.

Abbvie Inc.

Jun Shao

Michael James Cope

Eric F Connor

Jerry M Buysse

Dominique Charmot

Gerrit Klaerner

Deidre Madsen

Angela Lee

John Fordtran

Han Ting Chang

Elizabeth Goka

YongQi Mu

Scott J Hecker

Paul Mansky

Futian Liu

Mingjun Liu

Han-Ting Chang

Kalpesh N Biyani

David E Bergbreiter

Florence Roger

Faleh Salaymeh

Son Hoai Nguyen

Jonathan Mills

Inez Lees

Hongmin Zhang

Grace Huynh

Jordan Kopping

Robert Alpern

Dawn Parsell Otto

Yongqi Mu

Grace Quaker

Tomasz W Glinka

Timothy A Robbins

Tony Kwok-Kong Mong

Shiah-yun Chen

Damien Cartigny

Helen Zhu

Gerrit Klaemer

Xinnan Zhang

Grace May

Felah Salaymeh

Jordon Kopping

The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable pharmaceutical composition and may be used, for example, to treat eubicarbonatemic metabolic acidosis.

Compositions for and method of treating acid-base disorders

The present invention provides a crosslinked amine and amide polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritis, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like.

Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants

The present invention provides crosslinked amine polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritus, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like.

Amine polymers for use as bile acid sequestrants

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

Methods and compositions for treatment of ion imbalances

Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.

Anion-binding polymers and uses thereof

Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject.

Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors

Pharmaceutical compositions comprising cross-linked small molecule amine polymers

Treatment of hyperphosphatemia using crosslinked small molecule amine polymers

This invention is directed to processes for making substituted thiazoles. The substituted thiazole, ethyl 2-(4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate, also known as TEI-6720, is useful for treatment of gout and hyperuricemia. This compound belongs to a class of substituted thiazoles that inhibit xanthine oxidase and thus block uric acid production.

Substituted thiazoles

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.

Ion binding polymers and uses thereof

Growing community of inventors

Fremont, CA, United States of America

Jun Shao